Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
December 2016

Botulinum Toxin for Borderline Personality Disorder?
In a small open-label case series, patients with borderline personality disorder benefited from botulinum toxin injections.

Lamotrigine: Brand-Name versus Generic
Two studies found no significant changes in blood levels or pharmacokinetic variables when patients with seizure disorders were switched between brand-name lamotrigine (Lamictal and others) and various generic formulations.

Drugs to Help Smokers Quit: New Data
A new study comparing varenicline (Chantix) and bupropion (Wellbutrin, Zyban, and others) with a nicotine patch and placebo in smokers with and without psychiatric diagnoses reports no significant difference in neuropsychiatric adverse events among the four treatment groups.

Antipsychotics, Pneumonia, and Alzheimer Disease
A large study in Finland found that antipsychotic use was associated with an increased risk of pneumonia both in patients with and those without Alzheimer disease.

In Brief
Children with Hypertension Score Lower on Neurocognitive Tests; Use of Hormonal Contraception in Women Linked to Depression

BTP's 40th Year
The next issue of this newsletter, January 2017, will mark the start of our 40th annual volume.

CME 2016
Please be sure to submit the Continuing Medical Education (CME) posttest and evaluation for 2016. You can complete the test online or print it out and then submit by email or fax.

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.